Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Burfiralimab - ImmuneMed

Next Previous
Drug Profile

Burfiralimab - ImmuneMed

Alternative Names: hzVSF; hzVSF-v13; IgG4 - ImmuneMed

Latest Information Update: 10 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneMed
  • Class Anti-infectives; Anti-inflammatories; Antipsoriatics; Antivirals; Hepatoprotectants; Immunoglobulins; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID-19 pneumonia; Hepatitis B
  • No development reported Alcoholic hepatitis; Non-alcoholic steatohepatitis; Pneumonia; Psoriasis; Scleroderma

Most Recent Events

  • 10 Sep 2025 ImmuneMed prematurely terminates a phase II trial in Rheumatoid arthritis (Treatment-experienced) in Netherlands, Spain, Czech Republic, Netherlands, Hungary, Poland, Austria (IV, Infusion) (NCT06306339) (CTIS2023-507944-35-00)
  • 28 Feb 2025 No recent reports of development identified for research development in Alcoholic-hepatitis in South Korea (Parenteral)
  • 28 Feb 2025 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in South Korea (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top